Differential killing of the patient's cancer cells versus normal cells is a necessity for
chemotherapy. Advantage can be taken of close regulations of gene expression and of enzyme …

… whereas OXPHOS prevails in differentiated cells [180,181]. Interestingly, IF1 also plays a
relevant role in metabolic reprogramming during differentiation of human mesenchymal stem …

… will have one or more recurrences after initial treatment, and … squamous differentiation,
histopathological stage, and tumor … can serve to validate progression targets identified using DNA …

… the differentiated tumors are less responsive to therapy compared to rapidly proliferating
partially differentiated tumors… The employment of mathematics allows us to target therapy to any …

… aggressive course in PTC is the high rate (>70%) of BRAF mutations in tumor tissue of
patients enrolled in a recent clinical trial for treatment-resistant differentiated thyroid cancer [18•] . …

… in tumour growth, progression or survival. Several targeted therapies with anti-tumour activity
in human cancer … to produce objective responses, delay disease progression and, in some …

… -positive patients and in less-differentiated tumors (31). Kaplan-… As therapeutic agents,
miRNAs were employed to enhance … damage repair and cell cycle progression targets (41–43). …

… patients who were sensitive to antioxidant therapy to conduct differential gene functional
enrichment analysis and predict potential therapeutic drugs. Diagnostic markers between …

… , and consequent better survival rates observed in females, supporting the idea that modulating
the ERα-Gα12 pathway may be utilized for sex differential approaches in HCC treatment. …

… can only be provided when the incidence of the disease is diagnosed in the early stages, …
disease progression since they are involved in essential processes such as cell differentiation, …